Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Evolutionary Genomics, Inc. (FNAM)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
4220 Morning Star Drive 80108
Castle Rock, CO, US
Castle Rock, CO, US
CEO
Steven Bryan Warnecke
Website
evolgen.com
IPO
2011-04-08
CIK 884363 ISIN US30051F1012
Description
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governmental organizations, non-profit foundations, and commercial entities. The company is based in Castle Rock, Colorado.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| EG | OTC | 2015-04-02 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
195
Beta
-0.13
Float Shares
4.48M
Free Float %
67.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.97% | -99.99% | -99.99% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Quality scores
Altman Z-Score
-14.34
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+32.7% ★ Q4'22: +65.2% (vs Q4'21)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-121.1% Q4'22: +68.0% (vs Q4'21)
-
Share dilution Biotechnology: -3.4%+9.8% Q4'22: +13.1% (vs Q4'21)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-4.10× Q4'22: -5.97× (vs Q4'21)
Valuation Multiples
From
To
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-640.9K
OE per share TTM
-0.10
Owner's Yield
-48,153.09%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
131.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
6
Shares acquired
—
Shares disposed
333.3K
Cash buys
—
Cash sales
—
Net activity
-333,333
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-23 | WARNECKE STEVE B | Director / Officer / 10% Owner | M-Exempt | D | Stock Option (right to buy) | 66,667 | 0.55 | 36.7K | 0 | — | ↗ |
| 2022-05-23 | Orndorff Virginia P. | Director | M-Exempt | D | Stock Option (right to buy) | 20,000 | 0.00 | — | 0 | — | ↗ |
| 2022-05-23 | Messier Walter | Officer | F-InKind | D | Common Stock | 78,571 | 0.70 | 55.0K | 182,044 | — | ↗ |
| 2022-03-25 | WARNECKE STEVE B | Director / Officer / 10% Owner | A-Award | A | Stock Options (right to Buy) | 133,333 | 0.83 | 110.0K | 133,333 | — | ↗ |
| 2021-05-19 | WARNECKE STEVE B | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 37,500 | 0.00 | — | 1,864,588 | — | ↗ |
| 2020-12-30 | WARNECKE STEVE B | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 15,000 | 0.00 | — | 1,902,088 | — | ↗ |
| 2019-10-28 | WARNECKE STEVE B | Director / Officer / 10% Owner | A-Award | A | Stock Options (Right to Buy) | 150,000 | 1.65 | 247.5K | 150,000 | — | ↗ |
| 2019-10-28 | Orndorff Virginia P. | Director | A-Award | A | Stock Options (Right to Buy) | 45,000 | 1.50 | 67.5K | 45,000 | — | ↗ |
| 2019-10-28 | Boggess Mark Virgil | Director | A-Award | A | Stock Options (Right to Buy) | 45,000 | 1.50 | 67.5K | 45,000 | — | ↗ |
| 2016-09-09 | WARNECKE STEVE B | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 120,752 | 0.00 | — | 1,932,088 | — | ↗ |
| 2016-02-19 | WARNECKE STEVE B | Director / Officer / 10% Owner | A-Award | A | Stock Options (Right to Buy) | 100,000 | 3.30 | 330.0K | 100,000 | — | ↗ |
| 2016-02-19 | Orndorff Virginia P. | Director | A-Award | A | Stock Options (Right to Buy) | 15,000 | 3.00 | 45.0K | 15,000 | — | ↗ |
| 2016-02-19 | Boggess Mark Virgil | Director | A-Award | A | Stock Options (Right to Buy) | 15,000 | 3.00 | 45.0K | 15,000 | — | ↗ |
| 2015-10-19 | Orndorff Virginia P. | Director | — | D | Common Stock | 0 | 0.00 | — | 119,204 | — | ↗ |
| 2015-10-19 | Boggess Mark Virgil | Director | — | D | Common Stock | 0 | 0.00 | — | 26,000 | — | ↗ |
| 2014-10-01 | WARNECKE STEVE B | Director / Officer / 10% Owner | A-Award | A | Common Stock | 5,201,423 | 0.02 | 109.2K | 5,933,423 | — | ↗ |
| 2014-10-01 | SCHWARTZ SANFORD | — | S-Sale | D | Common Stock | 1,530,901 | 0.02 | 32.1K | 80,574 | — | ↗ |
| 2014-10-01 | FRIESS MICHAEL | — | S-Sale | D | Common Stock | 1,530,901 | 0.02 | 32.1K | 80,574 | — | ↗ |
| 2014-06-16 | WARNECKE STEVE B | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 732,000 | — | ↗ |
| 2010-11-23 | SCHWARTZ SANFORD | Director / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,977,475 | — | ↗ |
| 2010-11-23 | FRIESS MICHAEL | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,977,475 | — | ↗ |
| 2010-11-23 | DiVita Chloe M | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
6.66M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Walter Messier | Founder, Chief Technology Officer, Treasurer & Secretary | 150.0K | — |
| Steve Warnecke | Chairman, Chief Executive Officer, President & Chief Financial Officer | 140.1K | male |
| Virginia Orndorff | Founder & Director | 10.0K | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FNAM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
